Hyun Kuk Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyun Kuk Kim has a total of 336 co-authors. Here are the top co-authors by number of shared publications:
- Sung Soo Kim
Department of Cardiovascular Medicine, Chosun University Medical School, Gwangju, Korea
17 shared publications - Young Joon Hong
Department of Cardiology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, South Korea
16 shared publications - Myung Ho Jeong
Department of Cardiology, Chonnam National University Medical School, Gwangju, Korea
15 shared publications - Chang-Wook Nam
Department of Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea
14 shared publications - Joo-Yong Hahn
Sungkyunkwan University School of Medicine
14 shared publications - Joo Myung Lee
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
13 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Differential Prognostic Impact of Potent P2Y 12 Inhibitors in Patients With Acute Myocardial Infarction by Bleeding Risk
Joh HS, et al. Korean Circ J. 2027 ;57:e23. https://doi.org/10.4070/kcj.2026.0033
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessDifferential Prognostic Impact of Potent P2Y 12 Inhibitors in Patients With Acute Myocardial Infarction by Bleeding Risk
Joh HS, et al. Korean Circ J. 2027 ;57:e23. https://doi.org/10.4070/kcj.2026.0033
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Tailored Calibration Approach for Hemodynamic Boundary Conditions in CT-FFR
Kim YA, et al. Korean Circ J. 2027 ;57:e20. https://doi.org/10.4070/kcj.2025.0535
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessTailored Calibration Approach for Hemodynamic Boundary Conditions in CT-FFR
Kim YA, et al. Korean Circ J. 2027 ;57:e20. https://doi.org/10.4070/kcj.2025.0535
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Artificial Intelligence‐Driven Angiographic Quantification of Fractional Flow Reserve: Proof‐of‐Concept Validation Study
Background: Angiography‐based fractional flow reserve (FFR) techniques offer wire‐free alternatives but often require manual segmentation and 3‐dimensional reconstruction. Although an artificial intelligence‐driven approach automates these steps, validation remains limited. This study investigated the diagnostic performance of an artificial intelligence‐driven angiography‐based FFR (medipixel FFR [MPFFR]), compared with quantitative flow ratio (QFR) in predicting functionally significant coronary artery stenosis defined by FFR ≤0.80. Methods: A total of 599 vessels from 452 patients who underwent clinically indicated FFR measurement were prospectively enrolled from 5 university hospitals in Korea. MPFFR used automated processes in frame selection, artificial intelligence contour detection, corresponding points matching, 3‐dimensional reconstruction, and analytical hemodynamic modeling. The primary end point was diagnostic accuracy for detecting FFR ≤0.80. Secondary end points were target vessel failure (composite of cardiac death, target‐vessel myocardial infarction, and target‐vessel revascularization) at 2 years. Results: Mean analysis time of MPFFR was 12.5±1.7 seconds and manual correction was needed in 32 vessels (5.3%). MPFFR showed similar diagnostic performance with QFR (correlation with FFR; MPFFR versus QFR: R=0.885 versus R=0.860, P for comparison=0.011; area under the curve to predict FFR ≤0.80; 0.949 versus 0.953, P for comparison=0.631). At a median follow‐up of 2 years (interquartile range, 1.6–2.6 years), patients with MPFFR ≤0.80 had higher risk of target vessel failure than those with MPFFR >0.80 (4.5% versus 0.8%; adjusted hazard ratio, 5.94 [95% CI, 1.27–27.91]; P =0.024). C‐index to predict target vessel failure was comparable between MPFFR and QFR (0.770 versus 0.753, P for comparison=0.469). Conclusions: In this multicenter registry, an artificial intelligence‐driven angiography‐based FFR demonstrated comparable diagnostic accuracy with QFR in identifying functionally significant stenosis, and similar prognostic ability with QFR in terms of target vessel failure at 2 years. Registration: Multicenter QFR Registry; Unique Identifier: NCT03791788.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Open AccessArtificial Intelligence‐Driven Angiographic Quantification of Fractional Flow Reserve: Proof‐of‐Concept Validation Study
Background: Angiography‐based fractional flow reserve (FFR) techniques offer wire‐free alternatives but often require manual segmentation and 3‐dimensional reconstruction. Although an artificial intelligence‐driven approach automates these steps, validation remains limited. This study investigated the diagnostic performance of an artificial intelligence‐driven angiography‐based FFR (medipixel FFR [MPFFR]), compared with quantitative flow ratio (QFR) in predicting functionally significant coronary artery stenosis defined by FFR ≤0.80. Methods: A total of 599 vessels from 452 patients who underwent clinically indicated FFR measurement were prospectively enrolled from 5 university hospitals in Korea. MPFFR used automated processes in frame selection, artificial intelligence contour detection, corresponding points matching, 3‐dimensional reconstruction, and analytical hemodynamic modeling. The primary end point was diagnostic accuracy for detecting FFR ≤0.80. Secondary end points were target vessel failure (composite of cardiac death, target‐vessel myocardial infarction, and target‐vessel revascularization) at 2 years. Results: Mean analysis time of MPFFR was 12.5±1.7 seconds and manual correction was needed in 32 vessels (5.3%). MPFFR showed similar diagnostic performance with QFR (correlation with FFR; MPFFR versus QFR: R=0.885 versus R=0.860, P for comparison=0.011; area under the curve to predict FFR ≤0.80; 0.949 versus 0.953, P for comparison=0.631). At a median follow‐up of 2 years (interquartile range, 1.6–2.6 years), patients with MPFFR ≤0.80 had higher risk of target vessel failure than those with MPFFR >0.80 (4.5% versus 0.8%; adjusted hazard ratio, 5.94 [95% CI, 1.27–27.91]; P =0.024). C‐index to predict target vessel failure was comparable between MPFFR and QFR (0.770 versus 0.753, P for comparison=0.469). Conclusions: In this multicenter registry, an artificial intelligence‐driven angiography‐based FFR demonstrated comparable diagnostic accuracy with QFR in identifying functionally significant stenosis, and similar prognostic ability with QFR in terms of target vessel failure at 2 years. Registration: Multicenter QFR Registry; Unique Identifier: NCT03791788.
- 28 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Microvascular resistance reserve and cardiovascular outcomes: the FLOW-CMD registry
Background and Aims: Microvascular resistance reserve (MRR) is a novel index for assessing coronary microvascular function that is independent of epicardial coronary artery stenosis and subtended myocardial mass. However, limited data are available regarding the clinical relevance of coronary microvascular dysfunction, defined by MRR, in patients undergoing clinically indicated invasive coronary angiography. This study sought to evaluate the incidence and prognostic impact of coronary microvascular dysfunction defined by MRR in routine practice. Methods: In the prospective, multicentre FLOW-CMD Registry, 1003 consecutive patients with suspected ischaemic heart disease who underwent clinically indicated invasive coronary angiography with comprehensive coronary physiologic assessment were prospectively enrolled. Coronary microvascular dysfunction was defined as MRR ≤2.5 in any evaluated vessel. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularization, or hospitalization for heart failure. Results: Coronary microvascular dysfunction was identified in 334 of 1003 patients (33.3%). MRR as a continuous variable was associated with the risk of the primary endpoint (hazard ratio [HR] per 1-unit decrease, 1.16; 95% confidence interval [CI] 1.03–1.32; P = .026). At a median follow-up of 1.9 years, the primary endpoint occurred in 47 of 334 patients (18.2%) with coronary microvascular dysfunction and 49 of 669 patients (8.6%) with preserved microvascular function (HR 1.94; 95% CI 1.30–2.90; P = .001). On multivariable analysis, coronary microvascular dysfunction defined by MRR ≤2.5 was independently associated with the primary endpoint (adjusted HR 1.78; 95% CI 1.06–2.99; P = .030). Conclusions: In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction defined by MRR ≤2.5 was observed among one-third of patients, and was associated with an increased risk of a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularization, or hospitalization for heart failure (Multicenter FLOW-CMD Registry ClinicalTrials.gov number, NCT05369182).
- 28 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Microvascular resistance reserve and cardiovascular outcomes: the FLOW-CMD registry
Background and Aims: Microvascular resistance reserve (MRR) is a novel index for assessing coronary microvascular function that is independent of epicardial coronary artery stenosis and subtended myocardial mass. However, limited data are available regarding the clinical relevance of coronary microvascular dysfunction, defined by MRR, in patients undergoing clinically indicated invasive coronary angiography. This study sought to evaluate the incidence and prognostic impact of coronary microvascular dysfunction defined by MRR in routine practice. Methods: In the prospective, multicentre FLOW-CMD Registry, 1003 consecutive patients with suspected ischaemic heart disease who underwent clinically indicated invasive coronary angiography with comprehensive coronary physiologic assessment were prospectively enrolled. Coronary microvascular dysfunction was defined as MRR ≤2.5 in any evaluated vessel. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularization, or hospitalization for heart failure. Results: Coronary microvascular dysfunction was identified in 334 of 1003 patients (33.3%). MRR as a continuous variable was associated with the risk of the primary endpoint (hazard ratio [HR] per 1-unit decrease, 1.16; 95% confidence interval [CI] 1.03–1.32; P = .026). At a median follow-up of 1.9 years, the primary endpoint occurred in 47 of 334 patients (18.2%) with coronary microvascular dysfunction and 49 of 669 patients (8.6%) with preserved microvascular function (HR 1.94; 95% CI 1.30–2.90; P = .001). On multivariable analysis, coronary microvascular dysfunction defined by MRR ≤2.5 was independently associated with the primary endpoint (adjusted HR 1.78; 95% CI 1.06–2.99; P = .030). Conclusions: In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction defined by MRR ≤2.5 was observed among one-third of patients, and was associated with an increased risk of a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularization, or hospitalization for heart failure (Multicenter FLOW-CMD Registry ClinicalTrials.gov number, NCT05369182).
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e042507
Clinical Outcomes of Complete Revascularization in Acute Myocardial Infarction Patients With High Bleeding Risk and Multivessel Disease
Background: High bleeding risk (HBR) is associated with an increased risk of both ischemic and bleeding events and is known to have a worse prognosis than non‐HBR in patients with acute myocardial infarction. However, data regarding the prognostic impact of complete revascularization (CR) in acute myocardial infarction and multivessel disease patients complicated by HBR remain limited. Methods: A total of 13 460 patients with acute myocardial infarction and multivessel disease who underwent successful percutaneous coronary intervention for infarct‐related artery were selected from the nationwide Korean registry from 2011 to 2020. Primary outcome was major adverse cardiac and cerebrovascular events during 3 years of follow‐up. Results: Of the 13 460 patients, 4401 (32.7%) were classified as the group with HBR according to modified Academic Research Consortium‐HBR criteria and 1577 patients (35.8%) underwent CR. Among the group without HBR, 3911 patients (43.2%) underwent CR for noninfarct‐related artery. The group with HBR had significantly higher risk of major adverse cardiac and cerebrovascular events (non‐HBR versus HBR; 16.4% versus 35.7%; adjusted hazard ratio [HR], 1.70 [95% CI, 1.56–1.85]; P P P P P =0.572) and without HBR (4.2% versus 5.0%, adjusted HR, 0.98 [95% CI, 0.78–1.23], P =0.867). Conclusions: In patients with acute myocardial infarction and multivessel disease, CR was associated with a lower risk of major adverse cardiac and cerebrovascular events compared with incomplete revascularization in both HBR and non‐HBR. Registration: KAMIR‐NIH; KCT‐0000863, KAMIR‐V; KCT‐0008355.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e042507
Clinical Outcomes of Complete Revascularization in Acute Myocardial Infarction Patients With High Bleeding Risk and Multivessel Disease
Background: High bleeding risk (HBR) is associated with an increased risk of both ischemic and bleeding events and is known to have a worse prognosis than non‐HBR in patients with acute myocardial infarction. However, data regarding the prognostic impact of complete revascularization (CR) in acute myocardial infarction and multivessel disease patients complicated by HBR remain limited. Methods: A total of 13 460 patients with acute myocardial infarction and multivessel disease who underwent successful percutaneous coronary intervention for infarct‐related artery were selected from the nationwide Korean registry from 2011 to 2020. Primary outcome was major adverse cardiac and cerebrovascular events during 3 years of follow‐up. Results: Of the 13 460 patients, 4401 (32.7%) were classified as the group with HBR according to modified Academic Research Consortium‐HBR criteria and 1577 patients (35.8%) underwent CR. Among the group without HBR, 3911 patients (43.2%) underwent CR for noninfarct‐related artery. The group with HBR had significantly higher risk of major adverse cardiac and cerebrovascular events (non‐HBR versus HBR; 16.4% versus 35.7%; adjusted hazard ratio [HR], 1.70 [95% CI, 1.56–1.85]; P P P P P =0.572) and without HBR (4.2% versus 5.0%, adjusted HR, 0.98 [95% CI, 0.78–1.23], P =0.867). Conclusions: In patients with acute myocardial infarction and multivessel disease, CR was associated with a lower risk of major adverse cardiac and cerebrovascular events compared with incomplete revascularization in both HBR and non‐HBR. Registration: KAMIR‐NIH; KCT‐0000863, KAMIR‐V; KCT‐0008355.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5 (4) , 391
From Unsustainable Effort to Healthy Habits: A New Model in Cardiac Rehabilitation
Kim HK. J Cardiovasc Interv. 2026 ;5:e31. https://doi.org/10.54912/jci.2026.0023
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5 (4) , 391
Open AccessFrom Unsustainable Effort to Healthy Habits: A New Model in Cardiac Rehabilitation
Kim HK. J Cardiovasc Interv. 2026 ;5:e31. https://doi.org/10.54912/jci.2026.0023
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56
2026 Focus Update of the 2021 Korean Society of Myocardial Infarction Expert Consensus Document on Revascularization for Acute Coronary Syndromes
This focused update from the Korean Society of Myocardial Infarction provides consensus recommendations for revascularization in acute coronary syndrome (ACS), integrating major trial evidence since 2021 with Korean real-world practice. A multidisciplinary writing committee reviewed randomized trials, meta-analyses, and recent guidelines, and achieved consensus document. Key recommendations are as follows: 1) Cardiogenic shock: prioritize culprit-first revascularization with early reassessment; apply mechanical circulatory support selectively, guided by shock phenotype and escalation criteria rather than routine use; 2) Non-ST segment elevation ACS: use risk-stratified invasive timing with clear triggers for urgent versus early angiography; 3) Access and imaging: adopt radial-first access and broaden intravascular imaging for complex anatomy, ambiguous culprit lesions, and optimization of stent expansion; 4) Non-culprit lesion: favor complete revascularization in ST-segment elevation myocardial infarction (MI) with multivessel disease; select immediate versus staged procedures based on hemodynamics, ischemic burden, renal function, and contrast load. (5) Special scenarios: implement mechanism-based pathways for MI with non-obstructive coronary arteries and spontaneous coronary artery dissection (SCAD), incorporating intracoronary imaging, functional testing, vasospasm provocation, and cardiac magnetic resonance imaging; prefer conservative treatment for SCAD unless ongoing ischemia persists. The document provides concise "do" statements, and a summary of changes from 2021 to facilitate bedside adoption. These recommendations aim to standardize high-value, patient-centered ACS care in Korea, reduce practice variability, and improve outcomes while acknowledging areas requiring further evidence.
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56
Open Access2026 Focus Update of the 2021 Korean Society of Myocardial Infarction Expert Consensus Document on Revascularization for Acute Coronary Syndromes
This focused update from the Korean Society of Myocardial Infarction provides consensus recommendations for revascularization in acute coronary syndrome (ACS), integrating major trial evidence since 2021 with Korean real-world practice. A multidisciplinary writing committee reviewed randomized trials, meta-analyses, and recent guidelines, and achieved consensus document. Key recommendations are as follows: 1) Cardiogenic shock: prioritize culprit-first revascularization with early reassessment; apply mechanical circulatory support selectively, guided by shock phenotype and escalation criteria rather than routine use; 2) Non-ST segment elevation ACS: use risk-stratified invasive timing with clear triggers for urgent versus early angiography; 3) Access and imaging: adopt radial-first access and broaden intravascular imaging for complex anatomy, ambiguous culprit lesions, and optimization of stent expansion; 4) Non-culprit lesion: favor complete revascularization in ST-segment elevation myocardial infarction (MI) with multivessel disease; select immediate versus staged procedures based on hemodynamics, ischemic burden, renal function, and contrast load. (5) Special scenarios: implement mechanism-based pathways for MI with non-obstructive coronary arteries and spontaneous coronary artery dissection (SCAD), incorporating intracoronary imaging, functional testing, vasospasm provocation, and cardiac magnetic resonance imaging; prefer conservative treatment for SCAD unless ongoing ischemia persists. The document provides concise "do" statements, and a summary of changes from 2021 to facilitate bedside adoption. These recommendations aim to standardize high-value, patient-centered ACS care in Korea, reduce practice variability, and improve outcomes while acknowledging areas requiring further evidence.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5 (4) , 339
Antiplatelet Therapy in East Asian Patients With Acute Coronary Syndrome: Current Evidence and Evolving Strategies
Honda S, et al. J Cardiovasc Interv. 2026 ;5:e22. https://doi.org/10.54912/jci.2025.0047
- 1 January 2026
- Published by XMLink in Journal of Cardiovascular Intervention
- Vol. 5 (4) , 339
Open AccessAntiplatelet Therapy in East Asian Patients With Acute Coronary Syndrome: Current Evidence and Evolving Strategies
Honda S, et al. J Cardiovasc Interv. 2026 ;5:e22. https://doi.org/10.54912/jci.2025.0047
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (2) , 131-143
Diagnostic Performance of Angiography-Derived FFR According to the Analysis Factors
Ki YJ, et al. Korean Circ J. 2025 Sep;56:e9. https://doi.org/10.4070/kcj.2025.0077
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (2) , 131-143
Open AccessDiagnostic Performance of Angiography-Derived FFR According to the Analysis Factors
Ki YJ, et al. Korean Circ J. 2025 Sep;56:e9. https://doi.org/10.4070/kcj.2025.0077
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e043414
Clinical Relevance of Fractional Flow Reserve‐Guided Percutaneous Coronary Intervention According to Left Ventricular Ejection Fraction in Patients With Acute Myocardial Infarction and Multivessel Disease
Background: Fractional flow reserve (FFR)‐guided or angiography‐guided complete revascularization has not been evaluated in patients with acute myocardial infarction (AMI) with multivessel disease and reduced left ventricular ejection fraction (LVEF). This study sought to evaluate the impact of FFR‐guided percutaneous coronary intervention (PCI) for patients with AMI with multivessel disease according to left ventricular systolic function. Methods: We performed a prespecified analysis of the FRAME‐AMI (Fractional Flow Reserve Versus Angiography‐Guided Strategy in Acute Myocardial Infarction With Multivessel Disease) trial, which randomly allocated 562 patients to undergo either FFR‐guided PCI (FFR ≤0.80) or angiography‐guided PCI (diameter stenosis >50%) for non–infarct‐related arteries. Patients were classified into preserved (≥50%) and reduced (P P =0.004). Conversely, there was no significant difference in major adverse cardiovascular events between the FFR and angiography‐guided PCI among patients with reduced LVEF (17.0% versus 21.0%; HR, 0.64 [95% CI, 0.31–1.31]; P =0.225). In the exploratory analysis, the clinical benefit of FFR‐guided PCI was more evident with an increased LVEF (interaction P =0.028). Conclusions: In patients with AMI with multivessel disease, FFR‐guided PCI for a non–infarct‐related artery had differential clinical impact according to left ventricular systolic function. The beneficial effect of FFR‐guided PCI might be maximized among patients with preserved LVEF rather than reduced LVEF. Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT02715518.
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e043414
Open AccessClinical Relevance of Fractional Flow Reserve‐Guided Percutaneous Coronary Intervention According to Left Ventricular Ejection Fraction in Patients With Acute Myocardial Infarction and Multivessel Disease
Background: Fractional flow reserve (FFR)‐guided or angiography‐guided complete revascularization has not been evaluated in patients with acute myocardial infarction (AMI) with multivessel disease and reduced left ventricular ejection fraction (LVEF). This study sought to evaluate the impact of FFR‐guided percutaneous coronary intervention (PCI) for patients with AMI with multivessel disease according to left ventricular systolic function. Methods: We performed a prespecified analysis of the FRAME‐AMI (Fractional Flow Reserve Versus Angiography‐Guided Strategy in Acute Myocardial Infarction With Multivessel Disease) trial, which randomly allocated 562 patients to undergo either FFR‐guided PCI (FFR ≤0.80) or angiography‐guided PCI (diameter stenosis >50%) for non–infarct‐related arteries. Patients were classified into preserved (≥50%) and reduced (P P =0.004). Conversely, there was no significant difference in major adverse cardiovascular events between the FFR and angiography‐guided PCI among patients with reduced LVEF (17.0% versus 21.0%; HR, 0.64 [95% CI, 0.31–1.31]; P =0.225). In the exploratory analysis, the clinical benefit of FFR‐guided PCI was more evident with an increased LVEF (interaction P =0.028). Conclusions: In patients with AMI with multivessel disease, FFR‐guided PCI for a non–infarct‐related artery had differential clinical impact according to left ventricular systolic function. The beneficial effect of FFR‐guided PCI might be maximized among patients with preserved LVEF rather than reduced LVEF. Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT02715518.